Metabolic pathways inhibitors can affect the therapeutic efficiency of doxorubicin

Sara S. Hassan; Entisar J. Hamad Al Mukhtar; Kaiser N. Madlum

doi:10.53730/ijhs.v6nS2.7375

Authors

Sara S. Hassan Dept. of pharmacology and toxicology, college of medicine, University of Babylon, Iraq
Entisar J. Hamad Al Mukhtar Dept. of pharmacology and toxicology, college of medicine, University of Babylon, Iraq
Kaiser N. Madlum
kaiser.madlum@uobabylon.edu.iq
Dept. of human anatomy, college of medicine, University of Babylon, Iraq

Keywords:

colon cancer, SW480, 2-deoxy-d-glucose, metformin, doxorubicin

Abstract

Cancers are a group of diseases characterized by uncontrolled growth and the spread of abnormal cells . Colon cancer (CC) is one of the most aggressive tumor that leading to death in the world In this study, an attempt was made to evaluate the effect of different combinations of 2-deoxy-d-glucose, metformin, and doxorubicin on colon cancer cells viability. Results revealed a significant decrease in colon cancer viability after the treatment with combinations of (2-DG- metformin, 2-DG – Dox , and 2-DG- metformin - Dox) at certain concentrations.

Downloads

Download data is not yet available.

References

Labianca, Roberto, Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., de Braud, F., & Wils, J. (2010). Colon cancer. Critical Reviews in Oncology/Hematology, 74(2), 106–133. https://doi.org/10.1016/j.critrevonc.2010.01.010

Rajalekshmi M, Shreedhara CS, Lobo R, Rao PP. The review on genetics, epigenetics, risk factors and diagnosis of colon cancer. Vol. 11, Research Journal of Pharmacy and Technology. 2018.

Munker S, Gerken M, Fest P, Ott C, Schnoy E, Fichtner-Feigl S, et al. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. BMC Cancer. BMC Cancer; 2018;18:1–9.

Kurtoglu, M., Gao, N., Shang, J., Maher, J. C., Lehrman, M. A., et al. (2007) Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 6, 3049–3058.

Joshi RS, Nangare AK, Sanap DS, Sase SM. Development and Validation of UV-Spectrophotometric Method for Estimation of Metformin Hydrochloride and Pioglitazone in Tablet Dosage Form. J Drug Deliv Ther. 2019;9(4-A).

Rashid AI, Madlum KN, Ghaleb R, Obied HN, Enayah SH. Effects of antidiabetic drug on the anticancer activity of Cisplatin © Annals of Tropical Medicine & Public Health S280 © Annals of Tropical Medicine & Public Health S280. Annals of Tropical Medicine and Public Health. 2019;22.

. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: A comprehensive review of recent advances. Cancer Management and Research. 2019;11:3295–313.

El-ashmawy, N. E., Khedr, N. F., & El-bahrawy, H. A. (2017). Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. https://doi.org/10.1177/1010428317692235.

Locatelli, L., Cazzaniga, A., Fedele, G., Zocchi, M., Scrimieri, R., Moscheni, C., Castiglioni, S., & Maier, J. A. (2021). A comparison of doxorubicin-resistant colon cancer lovo and leukemia hl60 cells: Common features, different underlying mechanisms. Current Issues in Molecular Biology, 43(1), 163–175. https://doi.org/10.3390/cimb43010014.

Johnson-arbor, K., & Dubey, R. (2020). Doxorubicin.

Johan van Meerloo, Gertjan J.L. Kaspers and JC. Cancer Cell Culture. Cancer Cell Culture. 2011;731:237–45.

Kurtoglu M, Maher JC, Lampidis TJ. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxidants and Redox Signaling. 2007;9:1383–90.

Blum, R.; Kloog, Y. Metabolism addiction in pancreatic cancer. Cell Death Dis. 2014, 5, e1065.

Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., Dipaola, R. S., et al. (2013) A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother.

Tuccillo FM, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A, et al. Aberrant glycosylation as biomarker for cancer: Focus on CD43. BioMed Research International. Hindawi Publishing Corporation; 2014.

. Haffty, B. G. et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24, 5652–5657, doi:10.1200/JCO.2006.06.5664 (2006).

Saini N, Yang X. Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells. Acta Biochimica et Biophysica Sinica. 2017;50:133–43.

Coronel-herna J, Cantu D, Jacobo-herrera N, Millan-catalan O, Delgado-waldo I, Campos-parra AD, et al. Combination of Metformin , Sodium Oxamate and Doxorubicin Induces Apoptosis and Autophagy in Colorectal Cancer Cells via Downregulation HIF-1 a. 2021;11:1–13.

Lesan, V., Ghaffari, S. H., Salaramoli, J., Heidari, M., Rostami, M., Alimoghaddam, K., & Ghavamzadeh, A. (2014). Evaluation of antagonistic effects of metformin with cisplatin in gastric cancer cells. International Journal of Hematology-Oncology and Stem Cell Research, 8(3), 12–19.

Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. The Lancet Oncology [Internet]. Elsevier Ltd; 2016;17:475–83.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an anti- tumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576–86.

Locatelli, L., Cazzaniga, A., Fedele, G., Zocchi, M., Scrimieri, R., Moscheni, C., Castiglioni, S., & Maier, J. A. (2021). A comparison of doxorubicin-resistant colon cancer lovo and leukemia hl60 cells: Common features, different underlying mechanisms. Current Issues in Molecular Biology, 43(1), 163–175. https://doi.org/10.3390/cimb43010014 .

Putri, H., Jenie, R. I., Handayani, S., Kastian, R. F., & Meiyanto, E. (2016). Combination of potassium pentagamavunon-0 and doxorubicin induces apoptosis and cell cycle arrest and inhibits metastasis in breast cancer cells. Asian Pacific Journal of Cancer Prevention, 17(5), 2683–2688.

Lüpertz, R., Wätjen, W., Kahl, R., & Chovolou, Y. (2010). Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and 87 apoptotic cell death in human colon cancer cells. Toxicology, 271(3), 115–121. https://doi.org/10.1016/j.tox.2010.03.012

Emami RA, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci 2013;34:126–35.

Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Molecular Cancer Therapeutics. 2011;10:2350–62.

Bizjak M, Malavašič P, Dolinar K, Pohar J, Pirkmajer S. Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro. 2017;(October 2016):1–14.

Johnson-arbor K, Dubey R. Doxorubicin. 2020;

Yang, B., Chen, Y., & Shi, J. (2020). Tumor‐Specific Chemotherapy by Nanomedicine‐Enabled Differential Stress Sensitization. Angewandte Chemie, 132(24), 9780–9788.

Zhang, D., Li, J., Wang, F., Hu, J., Wang, S., & Sun, Y. (2014). 2- Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Letters, 355(2), 176–183.

Babichev Y, Kabaroff L, Datti A, Uehling D, Isaac M, Al-awar R, et al. Pi3k/Akt/mTOR Inhibition in Combination With Doxorubicin is an Effective Therapy for Leiomyosarcoma. J Trans Med (2016) 14:67. doi: 10.1186/s12967-016-0814-z.

El-Ashmawy NE, Khedr NF, El-Bahrawy HA, Abo Mansour HE. Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. Tumor Biology. May 2017.